Sales & Marketing News | pharmaphorum

News

Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis.

News

A multibillion-dollar partnership between AbbVie and Genmab risks being soured by a lawsuit claiming misappropriation of trade secrets.

News

DNA testing specialist 23andMe has filed for bankruptcy, prompting the resignation of co-founder and chief executive Anne Wojcicki.

News

AstraZeneca will open its sixth R&D centre in China, while J&J announces four new manufacturing facilities in the US in a major reshoring drive.

News

Novartis' oral complement inhibitor Fabhalta has become the first approved treatment for rare kidney disease C3G as it chases a $3bn sales target.

News

J&J's Tremfya gets a much-anticipated FDA approval for Crohn's disease, which the company thinks will be key to a renewed phase of sales growth.